title: Anti-Inflammatory Activity of Polysaccharide Fraction of Curcuma longa Extract (NR-INF-02).
abstract: The aim of the study was to investigate the safety and anti-inflammatory effects of polysaccharide fraction (F1) of Curcuma longa extract (NR-INF-02) in classical rodent models of inflammation. F1 was evaluated for its acute oral toxicity and found to be safe upto 5000 mg/kg body weight in rats. The anti-inflammatory activity of F1 was evaluated in acute (carrageenan - induced paw edema; xylene - induced ear edema) and chronic (cotton pellet - induced granuloma) models of inflammation. The results of the study demonstrated that F1 significantly (p ≤ 0.05) inhibited carrageenan-induced paw edema at 1 h and 3 h at doses of 11.25, 22.5 and 45 mg/kg body weight in rats. Also, F1 at doses of 15.75, 31.5 and 63 mg/kg significantly inhibited the xylene induced ear edema in mice. In a chronic model, F1 at 11.25, 22.5 and 45 mg/kg doses produced significant reduction of wet and dry weights of cotton pellets in rats. Overall results indicated that F1 of NR-INF-02 significantly attenuated acute and chronic inflammation in rodent models. This study emphasizes on the importance of Curcuma longa polysaccharide's role in acute and chronic inflammation.
authors.forename: Ramanaiah
authors.initials: R
authors.lastname: Illuri
authors.forename: Bharathi
authors.initials: B
authors.lastname: Bethapudi
authors.forename: Senthilkumar
authors.initials: S
authors.lastname: Anandakumar
authors.forename: Sasikumar
authors.initials: S
authors.lastname: Murugan
authors.forename: Joshua A
authors.initials: JA
authors.lastname: Joseph
authors.forename: Deepak
authors.initials: D
authors.lastname: Mundkinajeddu
authors.forename: Amit
authors.initials: A
authors.lastname: Agarwal
authors.affiliation: Department of Biology, Head of R&D Biology, Natural Remedies Pvt. Ltd., Bangalore, India. cvc@naturalremedy.com.
authors.forename: C V
authors.initials: CV
authors.lastname: Chandrasekaran
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D002351:Carrageenan / Q000008:administration & dosage; D005591:Chemical Fractionation; D030024:Curcuma; D004195:Disease Models, Animal; D004487:Edema / Q000139:chemically induced / Q000517:prevention & control*; D005260:Female; D006099:Granuloma / Q000517:prevention & control*; D006801:Humans; D008297:Male; D051379:Mice; D010936:Plant Extracts / Q000008:administration & dosage* / Q000009:adverse effects; D011134:Polysaccharides; D051381:Rats; D017208:Rats, Wistar; D014992:Xylenes / Q000008:administration & dosage
chemical_list: D000893:Anti-Inflammatory Agents; D010936:Plant Extracts; D011134:Polysaccharides; D014992:Xylenes; D002351:Carrageenan